Trial By Fire Solutions will be exhibiting SimpleTrials at the 2019 Global Annual Meeting of the Drug Industry Association (DIA). SimpleTrials is the first and only validated and full-featured Clinical Trial Management System (CTMS) offered as an on-demand subscription based application with plans starting at $99/month.
Trial By Fire Solutions, a leader in web-based clinical trial management solutions that improve planning, execution and tracking of clinical studies, will be showcasing new CTMS features at the SCOPE Summit 2019 on February 19-20 in Orlando, FL.
We’ve been receiving a lot of positive feedback from Sites, CROs and Sponsors about our contracts and payments features in SimpleTrials. Additionally, clients who have workflow separations between clinical, data management and finance team members find that SimpleTrials effectively handles their needs.
The eClinical innovators at Trial By Fire Solutions have added one more smart, useful and affordable tool to their SimpleTrials toolkit-- Electronic Data Capture (EDC) integration capability. SimpleTrials now has the ability to connect with external EDC systems to populate subject and subject visit data in the Clinical Trial Management System (CTMS). Once setup and enabled, this integration occurs on an automated daily basis, and alleviates the need to manually import or add individual subject records, subject visit dates and status.
The SimpleTrials team is in Boston this week continuing to build buzz around our versatile SimpleTrials CTMS toolkit at the Drug Industry Association (DIA) annual meeting. We are happy to re-connect with clients and EDC partners to share insight on how our on-demand CTMS is making it possible for teams in the Life Sciences Industry to manage their clinical study activities with ease. We are also delighted to continue conversations with prospective customers who are looking for an innovative CTMS that is cost effective, full featured and scalable for teams of all sizes.
Trial By Fire Solutions, an industry leader in web-based clinical trial management solutions, will be exhibiting SimpleTrials to a global audience at the 2018 annual meeting of the Drug Industry Association (DIA). The international event takes place at the Boston Convention and Exhibition Center beginning on June 25th, 2018. SimpleTrials is the first fully-featured Clinical Trial Management System (CTMS) built as an on-demand subscription based model with plans starting at $99/month.
We’re pleased to announce that we’ll be headed to Boston in late June to present SimpleTrials to an international audience at the 2018 annual meeting of the Drug Industry Association (DIA). The meeting will be taking place at the Boston Convention and Exhibition Center, and we will be exhibiting in Booth 1740 from Monday June 25th through Wednesday June 27th.
To meet the growing demand for affordable, on-demand clinical software, the team at Trial By Fire Solutions has released new subscription plans for the SimpleTrials Clinical Trial Management System (CTMS). With our dedication to making robust clinical software available to teams of all sizes and budgets, the SimpleTrials plans continue unprecedented affordability for a full-featured, well-designed CTMS, with plans starting at $99 per month for small teams. SimpleTrials continues to have no startup fees and no long term commitment, and SimpleTrials remains the most transparent CTMS on the market, with all pricing and legal agreements available on our website.
As a company committed to innovating well-designed clinical study management tools and making these tools affordable to all, we recently had two vendor engagements that reminded us why quality, transparency and experience in the Life Sciences industry really matter. In short, these are major drivers to the overall cost of healthcare and the availability of new therapies on the market!
At Trial By Fire Solutions, we remain committed to fiscal responsibility and ensuring our global footprint in the clinical trial management system (CTMS) market facilitates the development and availability of new therapies. We do this in a number of ways and we partner with vendors who share the same moral compass and fiscal stewardship.